Absolute Quantitation of Biotherapeutic Drug Product and Endogenous Protein in Human Serum Using a Hybrid Immunoassay-LC/MS Approach

Home > Science Hub > Absolute Quantitation of Biotherapeutic Drug Product and Endogenous Protein in Human Serum Using a Hybrid Immunoassay-LC/MS Approach
Back to the list

November 4, 2018

Simon Bourque, Sharon Y.T. Lin, Daniela Vasilescu, Rudolf Guilbaud, Michael Schirm and Lorella Di Donato

Absolute Quantitation of Biotherapeutic Drug Product and Endogenous Protein in Human Serum Using a Hybrid Immunoassay-LC/MS Approach, AAPS 2018

Absolute Quantitation of Biotherapeutic Drug Product and Endogenous Protein in Human Serum Using a Hybrid Immunoassay-LC/MS Approach

Download poster

You might also be interested by

Infographics

Supporting Your Targeted Protein Degradation Strategies

January 31, 2023

Proteomics/Mass Spectrometry

More info

CellTalk

Landmark study on metastatic breast cancer highlights the importance of identifying HER2-low patients

June 23, 2022

Proteomics/Mass Spectrometry

More info

Press Releases

CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays

May 19, 2022

Proteomics/Mass Spectrometry

More info

Brochures

High Performance Technologies for Cytokine Measurement

November 8, 2021

Immune Monitoring

More info